Kymera Therapeutics reported positive early results for its oral IRF5 degrader KT-579 and updated timelines for its two clinical programs. The company said it plans to begin testing KT-579 in lupus patients by early 2027, while its STAT6 degrader KT-621 is approaching a key atopic dermatitis data readout.
Kymera ended the third quarter with $1.6 billion in cash and expects its funding to last into 2029.
Key details
- KT-579 showed strong target engagement in healthy volunteers. In the completed Phase 1 trial, the drug produced deep, sustained IRF5 degradation. In multiple-dose testing, median degradation was at least 90% across several dose levels, with degradation reaching saturation by the third dose level. Drug exposure increased with dose, and the company described the safety profile as favorable.
- The trial supports KT-579’s biological mechanism, not yet its effectiveness in patients. Kymera also reported robust changes in disease-relevant biomarkers. The study involved healthy volunteers, so it does not establish whether the drug will improve symptoms or outcomes in lupus or other autoimmune diseases.
- A lupus trial is planned for early 2027. Kymera expects to start the Phase 1b LUMORA trial of KT-579 in lupus patients by then. The company is also exploring the program’s potential in other autoimmune diseases.
- KT-621’s atopic dermatitis trial has completed treatment and follow-up. The last participant completed the week 16 visit in the Phase 2b BROADEN2 study. Kymera expects to report topline results by year-end 2026.
- A Phase 3 atopic dermatitis trial is planned for mid-2027. That timing is subject to discussions with regulators.
- KT-621 asthma testing continues. Enrollment is ongoing in the Phase 2b BREADTH trial in moderate-to-severe eosinophilic asthma, with topline data expected in late 2027.
- Kymera also highlighted prior KT-621 findings. In September, it presented data from the Phase 1b BroADen atopic dermatitis trial at dermatology and respiratory medicine conferences.
Plain-English implications
The near-term clinical milestones are the BROADEN2 results expected by year-end 2026 and the planned start of KT-579 testing in lupus patients in early 2027. KT-579’s healthy-volunteer results provide evidence that the drug reaches and degrades its intended target, but patient trials will be needed to show whether that translates into clinical benefit.